Cingulate Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CING Nasdaq 2834 www.cingulate.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cingulate Inc.

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - Jun 18th, 2025 6:00 am
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - May 20th, 2025 6:00 am
CING: First Quarter 2025 Results - May 15th, 2025 6:27 am
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - May 14th, 2025 6:00 am
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - May 8th, 2025 2:30 pm
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - Apr 29th, 2025 6:00 am
Cingulate secures $3m to advance once-daily anxiety treatment - Apr 10th, 2025 8:16 am
CING: 2024 Financial and Operational Results - Apr 10th, 2025 3:38 am
Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone) - Apr 9th, 2025 6:00 am
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 - Apr 3rd, 2025 6:00 am
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved - Mar 26th, 2025 3:00 pm
CING: April Pre-NDA Meeting - Mar 10th, 2025 3:40 am
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025 - Mar 4th, 2025 7:00 am
Final Study Completed for Cingulate’s Lead Asset CTx-1301 - Jan 7th, 2025 5:30 am
Cingulate Inc Secures $5M Financing for Strategic Growth - Dec 24th, 2024 5:57 am
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - Dec 23rd, 2024 5:30 am
CING: Third Quarter Results - Nov 12th, 2024 1:15 am
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - Nov 7th, 2024 5:30 am
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - Oct 8th, 2024 1:15 pm
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 - Sep 12th, 2024 6:30 am